Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total transaction of $75,525.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,928,605.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Amicus Therapeutics Stock Down 0.3 %

Amicus Therapeutics stock opened at $10.40 on Friday. The company has a market cap of $3.08 billion, a P/E ratio of -20.39 and a beta of 0.80. Amicus Therapeutics, Inc. has a 1-year low of $9.70 and a 1-year high of $14.57. The company has a fifty day simple moving average of $11.55 and a 200 day simple moving average of $11.99. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 2.42.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The business had revenue of $115.08 million during the quarter, compared to the consensus estimate of $115.11 million. Research analysts anticipate that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Van ECK Associates Corp grew its position in shares of Amicus Therapeutics by 23.1% in the 4th quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 873 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Amicus Therapeutics by 97.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 3,638 shares during the period. Calton & Associates Inc. bought a new position in shares of Amicus Therapeutics in the 4th quarter valued at about $142,000. Park Avenue Securities LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter valued at about $128,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter valued at about $134,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on FOLD shares. JPMorgan Chase & Co. lowered their price objective on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a research report on Thursday, February 29th.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.